Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovacular Age-related Macular Degeneration (FOCU): Year 2 Reult Original Reearch Article

Purpoe To ae the efficacy and advere-event profile of combined treatment with ranibizumab and verteporfin photodynamic therapy (PDT) in patient with predominantly claic choroidal neovacularization (CNV) econdary to neovacular age-related macular degeneration. Deign Two-year, multicenter, randomized, ingle-maked, controlled tudy. Method Patient received monthly intravitreal injection of ranibizumab 0.5 mg (n = 106) or ham injection (n = 56). All patient received PDT on day zero, then quarterly a needed. Efficacy aement included change in viual acuity (VA) and leion characteritic and PDT frequency. Advere event were ummarized by incidence and everity. Reult At month 24, 88% of ranibizumab + PDT patient had lot <15 letter from baeline VA (v 75% for PDT alone), 25% had gained ≥15 letter (v 7% for PDT alone), and the two treatment arm differed by 12.4 letter in mean VA change (P < .05 for all between-group difference). The VA benefit of adding ranibizumab to PDT in year one perited through year two. On average, ranibizumab + PDT patient exhibited le leion growth and greater reduction of CNV leakage and ubretinal fluid accumulation, and required fewer PDT retreatment, than PDT-alone patient (mean = 0.4 v 3.0 PDT retreatment). Endophthalmiti and eriou intraocular inflammation occurred, repectively, in 2.9% and 12.4% of ranibizumab + PDT patient and 0% of PDT-alone patient. Incidence of eriou nonocular advere event were imilar in the two treatment group. Concluion Through two year, ranibizumab + PDT wa more effective than PDT alone and had a low rate of aociated advere event.